Skip to main content

Advertisement

SpringerLink
Log in

Lipid Composition of Whole Brain and Cerebellum in Hurler Syndrome (MPS IH) Mice

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Hurler syndrome (MPS IH) is caused by a mutation in the gene encoding alpha-L-iduronidase (IDUA) and leads to the accumulation of partially degraded glycosaminoglycans (GAGs). Ganglioside content is known to increase secondary to GAG accumulation. Most studies in organisms with MPS IH have focused on changes in gangliosides GM3 and GM2, without the study of other lipids. We evaluated the total lipid distribution in the whole brain and cerebellum of MPS IH (Idua −/−) and control (Idua +/?) mice at 6 months and at 12 months of age. The content of total sialic acid and levels of gangliosides GM3, GM2, and GD3 were greater in the whole brains of Idua −/− mice then in Idua +/? mice at 12 months of age. No other significant lipid differences were found in either whole brain or in cerebellum at either age. The accumulation of ganglioside GD3 suggests that neurodegeneration occurs in the Idua −/− mouse brain, but not to the extent seen in human MPS IH brain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bach G, Friedman R, Weissmann B et al (1972) The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. Proc Natl Acad Sci U S A 69:2048–2051

    Article  PubMed  CAS  Google Scholar 

  2. Fuller M, Brooks DA, Evangelista M et al (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 84:18–24

    Article  PubMed  CAS  Google Scholar 

  3. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171–180

    Article  PubMed  CAS  Google Scholar 

  4. Kelly TE (1976) The mucopolysaccharidoses and mucolipidoses. Clin Orthop Relat Res 116–133

  5. Brante G (1952) Gargoylism; a mucopolysaccharidosis. Scand J Clin Lab Invest 4:43–46

    Article  PubMed  CAS  Google Scholar 

  6. Leroy JG, Crocker AC (1966) Clinical definition of the Hurler-Hunter phenotypes. A review of 50 patients. Am J Dis Child 112:518–530

    PubMed  CAS  Google Scholar 

  7. Terlato NJ, Cox GF (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med 5:286–294

    Article  PubMed  CAS  Google Scholar 

  8. MacBrinn M, Okada S, Woollacott M et al (1969) Beta-galactosidase deficiency in the hurler syndrome. N Engl J Med 281:338–343

    Article  PubMed  CAS  Google Scholar 

  9. Abraham J, Chakrapani B, Singh M et al (1969) Hurler’s disease: a clinical and biochemical study of a case. Indian J Med Res 57:1761–1766

    PubMed  CAS  Google Scholar 

  10. Crawfurd M, Dean MF, Hunt DM et al (1973) Early prenatal diagnosis of Hurler’s syndrome with termination of pregnancy and confirmatory findings on the fetus. J Med Genet 10:144–153

    Article  PubMed  CAS  Google Scholar 

  11. Ellis RW (1936) Gargoylism (chondro-osteo-dystrophy, corneal opacities, hepatosplenomegaly, and mental deficiency). Proc R Soc Med 30:158–160

    PubMed  CAS  Google Scholar 

  12. Jervis GA (1942) Familial mental deficiency akin to amaurotic idiocy and gargoylism. An apparently new type. Arch Neurol Psychiatry 47:943–961

    Google Scholar 

  13. Booth DA, Goodwin H, Cumings JN (1966) Abnormal gangliosides in Tay-Sachs disease, Niemann-Pick’s disease, and gargoylism. J Lipid Res 7:337–340

    PubMed  CAS  Google Scholar 

  14. Clausen J, Dyggve HV, Melchior JC et al (1967) Chemical studies in gargoylism. Arch Dis Child 42:62–69

    Article  PubMed  CAS  Google Scholar 

  15. Constantopoulos G, Dekaban AS (1978) Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J Neurochem 30:965–973

    Article  PubMed  CAS  Google Scholar 

  16. Ledeen R, Salsman K, Gonatas J et al (1965) Structure Comparison of the major monosialogangliosides from brains of normal human, gargoylism, and late infantile systemic lipidosis. I. J Neuropathol Exp Neurol 24:341–351

    Article  PubMed  CAS  Google Scholar 

  17. Loeb H, Tondeur M, Toppet M et al (1969) Clinical, biochemical and ultrastructural studies of an atypical form of mucopolysaccharidosis. Acta Paediatr Scand 58:220–228

    Article  PubMed  CAS  Google Scholar 

  18. Lee C, Dineen TE, Brack M et al (1993) The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 14:1285–1292

    PubMed  CAS  Google Scholar 

  19. Clarke LA, Russell CS, Pownall S et al (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 6:503–511

    Article  PubMed  CAS  Google Scholar 

  20. Haskins ME, Jezyk PF, Desnick RJ et al (1979) Alpha-L-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I. Pediatr Res 13:1294–1297

    PubMed  CAS  Google Scholar 

  21. Spellacy E, Shull RM, Constantopoulos G et al (1983) A canine model of human alpha-L-iduronidase deficiency. Proc Natl Acad Sci U S A 80:6091–6095

    Article  PubMed  CAS  Google Scholar 

  22. Russell C, Hendson G, Jevon G et al (1998) Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 53:349–361

    Article  PubMed  CAS  Google Scholar 

  23. Ciron C, Desmaris N, Colle MA et al (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60:204–213

    Article  PubMed  CAS  Google Scholar 

  24. Constantopoulos G, Shull RM, Hastings N et al (1985) Neurochemical characterization of canine alpha-L-iduronidase deficiency disease (model of human mucopolysaccharidosis I). J Neurochem 45:1213–1217

    Article  PubMed  CAS  Google Scholar 

  25. Desmaris N, Verot L, Puech JP et al (2004) Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 56:68–76

    Article  PubMed  CAS  Google Scholar 

  26. Ellinwood NM, Colle MA, Weil MA et al (2007) Bone marrow transplantation for feline mucopolysaccharidosis I. Mol Genet Metab 91:239–250

    Article  PubMed  CAS  Google Scholar 

  27. Garcia-Rivera MF, Colvin-Wanshura LE, Nelson MS et al (2007) Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res Bull 74:429–438

    Article  PubMed  CAS  Google Scholar 

  28. Kakkis ED, Schuchman E, He X et al (2001) Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 72:199–208

    Article  PubMed  CAS  Google Scholar 

  29. McGlynn R, Dobrenis K, Walkley SU (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480:415–426

    Article  PubMed  CAS  Google Scholar 

  30. Shull RM, Helman RG, Spellacy E et al (1984) Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am J Pathol 114:487–495

    PubMed  CAS  Google Scholar 

  31. Ledeen R (1983) Gangliosides. In: Lajtha A (ed) Handbook of neurochemistry, vol 3. Plenum Publishing, New York, pp 41–90

    Google Scholar 

  32. Seyfried TN, Bernard DJ, Yu RK (1984) Cellular distribution of gangliosides in the developing mouse cerebellum: analysis using the staggerer mutant. J Neurochem 43:1152–1162

    Article  PubMed  CAS  Google Scholar 

  33. Seyfried TN, Miyazawa N, Yu RK (1983) Cellular localization of gangliosides in the developing mouse cerebellum: analysis using the weaver mutant. J Neurochem 41:491–505

    Article  PubMed  CAS  Google Scholar 

  34. Chou DK, Flores S, Jungalwala FB (1990) Identification of disialosyl paragloboside and O-acetyldisialosyl paragloboside in cerebellum and embryonic cerebrum. J Neurochem 54:1598–1607

    Article  PubMed  CAS  Google Scholar 

  35. Furuya S, Irie F, Hashikawa T et al (1994) Ganglioside GD1 alpha in cerebellar Purkinje cells. Its specific absence in mouse mutants with Purkinje cell abnormality and altered immunoreactivity in response to conjunctive stimuli causing long-term desensitization. J Biol Chem 269:32418–32425

    PubMed  CAS  Google Scholar 

  36. Seyfried TN, Yu RK (1984) Cellular localization of gangliosides in the mouse cerebellum: analysis using neurological mutants. Adv Exp Med Biol 174:169–181

    PubMed  CAS  Google Scholar 

  37. Seyfried TN, Yu RK (1990) Cerebellar ganglioside abnormalities in pcd mutant mice. J Neurosci Res 26:105–111

    Article  PubMed  CAS  Google Scholar 

  38. Svennerholm L, Bostrom K, Fredman P et al (1989) Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta 1005:109–117

    PubMed  CAS  Google Scholar 

  39. Nakatani Y, Yanagisawa M, Suzuki Y et al (2010) Characterization of GD3 ganglioside as a novel biomarker of mouse neural stem cells. Glycobiology 20:78–86

    Article  PubMed  CAS  Google Scholar 

  40. Seyfried TN, Yu RK, Miyazawa N (1982) Differential cellular enrichment of gangliosides in the mouse cerebellum: analysis using neurological mutants. J Neurochem 38:551–559

    Article  PubMed  CAS  Google Scholar 

  41. Yu RK, Iqbal K (1979) Sialosylgalactosyl ceramide as a specific marker for human myelin and oligodendroglial perikarya: gangliosides of human myelin, oligodendroglia and neurons. J Neurochem 32:293–300

    Article  PubMed  CAS  Google Scholar 

  42. Seyfried TN, Yu RK (1985) Ganglioside GD3: structure, cellular distribution, and possible function. Mol Cell Biochem 68:3–10

    PubMed  CAS  Google Scholar 

  43. Yu RK, Yen SI (1975) Gangliosides in developing mouse brain myelin. J Neurochem 25:229–232

    Article  PubMed  CAS  Google Scholar 

  44. Zalc B, Monge M, Dupouey P et al (1981) Immunohistochemical localization of galactosyl and sulfogalactosyl ceramide in the brain of the 30-day-old mouse. Brain Res 211:341–354

    Article  PubMed  CAS  Google Scholar 

  45. Muse ED, Jurevics H, Toews AD et al (2001) Parameters related to lipid metabolism as markers of myelination in mouse brain. J Neurochem 76:77–86

    Article  PubMed  CAS  Google Scholar 

  46. Borri PF, Hooghwinkel GJ, Edgar GW (1966) Brain ganglioside pattern in three forms of amaurotic idiocy and in gargoylism. J Neurochem 13:1249–1256

    Article  PubMed  CAS  Google Scholar 

  47. Ikeno T, Minami R, Tsugawa S et al (1982) Acidic glycosaminoglycans and gangliosides in the brains from four patients with genetic mucopolysaccharidosis. Tohoku J Exp Med 137:253–260

    Article  PubMed  CAS  Google Scholar 

  48. Baek RC, Kasperzyk JL, Platt FM et al (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52:1125–1133

    Article  PubMed  CAS  Google Scholar 

  49. Hauser EC, Kasperzyk JL, d’Azzo A et al (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem Genet 42:241–257

    Article  PubMed  CAS  Google Scholar 

  50. Kasperzyk JL, El-Abbadi MM, Hauser EC et al (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645–653

    Article  PubMed  CAS  Google Scholar 

  51. Seyfried TN, Glaser GH, Yu RK (1978) Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J Neurochem 31:21–27

    Article  PubMed  CAS  Google Scholar 

  52. Macala LJ, Yu RK, Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24:1243–1250

    PubMed  CAS  Google Scholar 

  53. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509

    PubMed  CAS  Google Scholar 

  54. Svennerholm L (1957) Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24:604–611

    Article  PubMed  CAS  Google Scholar 

  55. Ando S, Chang NC, Yu RK (1978) High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal Biochem 89:437–450

    Article  PubMed  CAS  Google Scholar 

  56. Melchior JC, Clausen J, Dyggve HV (1965) The mucopolysaccharisoses. A clinical and biochemical survey. Clin Pediatr (Phila) 4:468–480

    Article  CAS  Google Scholar 

  57. Uzman LL (1955) Chemical nature of the storage substance in gargoylism, Hurler-Pfaundler’s disease. AMA Arch Pathol 60:308–318

    PubMed  CAS  Google Scholar 

  58. Wherrett JR (1968) Analysis of glycolipids in the Hurler syndrome. Pathol Eur 3:431–439

    PubMed  CAS  Google Scholar 

  59. Constantopoulos G, Iqbal K, Dekaban AS (1980) Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem 34:1399–1411

    Article  PubMed  CAS  Google Scholar 

  60. Lekman AY, Hagberg BA, Svennerholm LT (1991) Membrane cerebral lipids in Rett syndrome. Pediatr Neurol 7:186–190

    Article  PubMed  CAS  Google Scholar 

  61. Levine SM, Seyfried TN, Yu RK et al (1986) Immunocytochemical localization of GD3 ganglioside to astrocytes in murine cerebellar mutants. Brain Res 374:260–269

    Article  PubMed  CAS  Google Scholar 

  62. Desplats PA, Denny CA, Kass KE et al (2007) Glycolipid and ganglioside metabolism imbalances in Huntington’s disease. Neurobiol Dis 27:265–277

    Article  PubMed  CAS  Google Scholar 

  63. Walkley SU, Baker HJ, Rattazzi MC et al (1991) Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J Neurol Sci 104:1–8

    Article  PubMed  CAS  Google Scholar 

  64. Denny CA, Desplats PA, Thomas EA et al. (2010) Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington’s Disease. J Neurochem

  65. Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32:89–103

    Article  PubMed  CAS  Google Scholar 

  66. Koudinov AR, Koudinova NV (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15:1858–1860

    PubMed  CAS  Google Scholar 

  67. Meertens L, Zhao Y, Rosic-Kablar S et al (2002) In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. Hum Gene Ther 13:1809–1820

    Article  PubMed  CAS  Google Scholar 

  68. Messina C, Rampazzo A, Cesaro S et al (2008) Eighteen-year follow-up of the first Italian MPSI patient treated with bone marrow transplantation. Bone Marrow Transplant 41:905–906

    Article  PubMed  CAS  Google Scholar 

  69. Hartung SD, Frandsen JL, Pan D et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9:866–875

    Article  PubMed  CAS  Google Scholar 

  70. Visigalli I, Delai S, Politi LS et al. (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects Mucopolysaccharidosis type I phenotype in the mouse model. Blood

  71. Wang D, Zhang W, Kalfa TA et al (2009) Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A 106:19958–19963

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work has been funded in part by the Minnesota Medical Foundation, Children’s Cancer Research Fund, MN (JT), NIH grant NS055195 and Boston College Research Expense Fund (TNS).

Author information

Authors and Affiliations

  1. Department of Biology, Boston College, 140 Commonwealth Ave, Chestnut Hill, Boston, MA, 02467, USA

    Karie A. Heinecke & Thomas N. Seyfried

  2. Department of Pediatrics, University of Minnesota, Minneapolis, MN, 55455, USA

    Brandon N. Peacock, Bruce R. Blazar & Jakub Tolar

Authors
  1. Karie A. Heinecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandon N. Peacock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce R. Blazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jakub Tolar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas N. Seyfried
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas N. Seyfried.

Additional information

Jakub Tolar and Thomas N. Seyfried contributed equally to this work.

Special Issue: In Honor of Dr. Robert Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heinecke, K.A., Peacock, B.N., Blazar, B.R. et al. Lipid Composition of Whole Brain and Cerebellum in Hurler Syndrome (MPS IH) Mice. Neurochem Res 36, 1669–1676 (2011). https://doi.org/10.1007/s11064-011-0400-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-011-0400-y

Keywords

Search

Navigation